• Research and Development

    Shaping the
    future of medicine
    Start »

12/09/14, Research and Development Bayer and DNDi Sign First Agreement to Develop an Innovative Oral Treatment for Human River Blindness more

12/01/14, Research and Development Bayer to Present Latest Data on Its Hematology and Oncology Portfolio Three-year results from the Phase III SPINART study for octocog alfa (Kogenate® FS) in patients with hemophilia A / New data on damoctocog alfa pegol (BAY 94-9027) for the treatment of hemophilia A / Presentations on copanlisib and sorafenib in patients with different hematological cancers more

At a glance


Research expenses 2013 EUR 1,654 million
In percent of division sales 2013
Employees in Research & Development 7,800
(as of Dec 31, 2013)
Main research sites Berlin and Wuppertal, Germany and Berkeley, USA
Research focus
  • Berlin:
    oncology, women's healthcare
  • Wuppertal:
    Cardiology, oncology
  • Berkeley:
    Applied research and life cycle management in hemophilia and multiple sclerosis


Image: Research and Development

Promising pipeline ensures mid- and long-term innovation

Bayer HealthCare Pharmaceuticals concentrates its R&D activities on innovative treatment alternatives for diseases with a high unmet medical need to improve patients’ quality of life and prolong lives. The focus is on therapeutic areas with a high medical need, where more innovations are needed despite considerable progress.

We hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.

Image: Clinical trials

About Clinical Trials

Clinical trials are used to evaluate potential treatments that have had some effect against disease in the lab, or in animal experiments. The whole point of a clinical trial is to find out if a treatment is effective.

Until sufficient results are available from many different trials it is just that, potential. Effectiveness of a treatment should never be at the expense of safety; the benefit of a treatment should always outweigh the harm and is fundamental to the conduct of all clinical trials.

Page tools
Interactive tool
Grants for Targets
Annual Report 2013
Clinical Trials


Copyright © Bayer Pharma AG